NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

muee88 Monday, 02/07/22 11:45:00 PM
Re: flipper44 post# 441910 0
Post #
442092
of 442166
NWBO submitted a response on 2/2. The most recent rejection included several ancillary things needing to be taken care of. This looks like it will be allowed now, which is great!


See paragraph 4 in the 4 page document."Argument" .First link below. The patent attorney pleads that all questions and / or objections raised by the patent reviewer have been addressed, and therefore the patent should be awarded.Any patent attorneys present to opine on this?



ae kusterer Monday, 02/07/22 05:44:59 PM
Re: None 0
Post #
442057
of 442146
How close is this application to awarded ?

https://patentcenter.uspto.gov/#!/applications/14533879/ifw/docs ( see 4 pages 2/2/22) (applicant argument) (see "Conclusion")

https://patentcenter.uspto.gov/#!/applications/14533879

ae kusterer Monday, 02/07/22 04:53:46 PM
Re: None 0
Post #
442050
of 442057

flipper44 Member Level Monday, 02/07/22 11:21:32 AM
Re: None 0.110
Post #
441875
of 442049
Very Recent Combination Patent application action:

Application Number: 14/533,879

02-04-2022 CRF Disk Has Been Received by Preexam / Group / PCT
02-02-2022 Substitute Specification Filed
02-07-2022 Date Forwarded to Examiner
02-02-2022 Response after Non-Final Action
02-02-2022 Request for Extension of Time - Granted
02-04-2022 CRF Is Good Technically / Entered into Database


pgsd Tuesday, 02/08/22 07:23:01 AM
Re: flipper44 post# 441910
Post #
442116
of 442155
Thanks Flipper, this is really interesting. In particular. the following:-

Prior Rejections

"Applicant thanks the Examiner for withdrawal of rejection of Claims 1,3,10,11,12,18,19,20,22,29,30,31,33,34,48 and 50 under 35 U.S.C. 103 as being unpatentable over Fadul in view of Jacobs and Dulos as well as the rejection of Claims 1,3,6,10,11,12,18,20,22,25.29-31.33.48 and 50 under 35 103 as being unpatentable over Yamanaka in view of Jacobs and Dulos"

IMO this is a really positive development. What appears to have happened is NWBO has submitted new articles that have convinced the examiner they were wrong in saying the claims were "unpatentable" The fact that the examiner has withdrawn the rejection IMO is huge as they could easily have just stuck with the decision.

Also, two other claims (19 and 34) the examiner states "would be allowable" if rewritten "in independent form including all the limitations of the base claim and any intervening claims"




flipper44 Member Level Tuesday, 02/08/22 05:05:55 AM
Re: flipper44 post# 441875 0
Post #
442097
of 442157
Four days ago: Italian meta-analysis of 15 small trials.

Published February 4, 2022

Quote:
In contrast, DCV (dendritic cell vaccination) led to significantly longer 1-year OS (HR = 1.936, 95% CI: 1.396–2.85, p = 0.001) and longer 2-year OS (HR = 3.670, 95% CI: 2.291–5.879, p = 0.001) versus control groups. Hence, introducing DCV could lead to increased 1 and 2-year survival of patients by 1.9 and 3.6 times, respectively. Conclusion: Antitumor regimens including DCV can effectively improve mid- term survival in patients suffering glioblastoma multiforme (GBM), but its impact emerges only after one year from vaccination. These data indicate the need for more time to achieve an anti-GBM immune response and suggest additional therapeutics, such as checkpoint inhibitors, to empower an earlier DCV action in (certain) patients affected by a very poor prognosis. https://mdpi-res.com/d_attachment/curroncol/curroncol-29-00075/article_deploy/curroncol-29-00075.pdf

Quote:
It should be noted that, as shown in Table 1, many studies integrated into this meta-analysis are of a non-randomized or historical type. This may reduce the statistical significance of the analysis.




InvestorsHub NewsWire
Robotic Assistance Devices Shipping Large Quantity of Units as Fiscal Year End Approaches • AITX • Feb 8, 2022 9:48 AM

Oncology Pharma Gives Update on Technology, Formulation and Data Creation • ONPH • Feb 8, 2022 9:30 AM

Ammo Inc. Board Approves up to $30 Million Dollar Repurchase Authorization • POWW • Feb 8, 2022 9:04 AM

Splash Beverage Group Signs Distribution Agreement with Anheuser-Busch Distributor Heimark Distributing for TapouT in Southern California • SBEV • Feb 8, 2022 9:03 AM

Mineworx Pleased with Court Decision • MWX • Feb 8, 2022 9:02 AM

Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecoxib Conjugate • ENVB • Feb 8, 2022 8:48 AM

Research Study Proves Calmer Canine Veterinary Therapy Device Resolves Separation Anxiety in Dogs • ADMT • Feb 7, 2022 2:51 PM

WPUR VERY BULLISH at $0.01 On Electric Utility And EV Charging News • ILST • Feb 7, 2022 2:18 PM

Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant - Moves Towards FDA/IND-Submission • IPA • Feb 7, 2022 11:24 AM

RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19 • RDHL • Feb 7, 2022 11:18 AM

HNRC UPDATES ON 18 MONTHS OF ACCOMPLISHMENTS • HNRC • Feb 7, 2022 11:04 AM

Start posting your company's news. Only $200 per official company press release!






ae kusterer Tuesday, 02/08/22 09:23:59 AM
Re: None 0
Post #
442153
of 442160

See paragraph 4 in the 4 page document."Argument" .First link below. The patent attorney pleads that all questions and / or objections raised by the patent reviewer have been addressed, and therefore the patent should be awarded.Any patent attorneys present to opine on this?



ae kusterer Monday, 02/07/22 05:44:59 PM
Re: None 0
Post #
442057
of 442146
How close is this application to awarded ?

https://patentcenter.uspto.gov/#!/applications/14533879/ifw/docs ( see 4 pages 2/2/22) (applicant argument) (see "Conclusion")

https://patentcenter.uspto.gov/#!/applications/14533879

ae kusterer Monday, 02/07/22 04:53:46 PM
Re: None 0
Post #
442050
of 442057

flipper44 Member Level Monday, 02/07/22 11:21:32 AM
Re: None 0.110
Post #
441875
of 442049
Very Recent Combination Patent application action:

Application Number: 14/533,879

02-04-2022 CRF Disk Has Been Received by Preexam / Group / PCT
02-02-2022 Substitute Specification Filed
02-07-2022 Date Forwarded to Examiner
02-02-2022 Response after Non-Final Action
02-02-2022 Request for Extension of Time - Granted
02-04-2022 CRF Is Good Technically / Entered into Database


pgsd Tuesday, 02/08/22 07:23:01 AM
Re: flipper44 post# 441910
Post #
442116
of 442155
Thanks Flipper, this is really interesting. In particular. the following:-

Prior Rejections

"Applicant thanks the Examiner for withdrawal of rejection of Claims 1,3,10,11,12,18,19,20,22,29,30,31,33,34,48 and 50 under 35 U.S.C. 103 as being unpatentable over Fadul in view of Jacobs and Dulos as well as the rejection of Claims 1,3,6,10,11,12,18,20,22,25.29-31.33.48 and 50 under 35 103 as being unpatentable over Yamanaka in view of Jacobs and Dulos"

IMO this is a really positive development. What appears to have happened is NWBO has submitted new articles that have convinced the examiner they were wrong in saying the claims were "unpatentable" The fact that the examiner has withdrawn the rejection IMO is huge as they could easily have just stuck with the decision.

Also, two other claims (19 and 34) the examiner states "would be allowable" if rewritten "in independent form including all the limitations of the base claim and any intervening claims"




flipper44 Member Level Tuesday, 02/08/22 05:05:55 AM
Re: flipper44 post# 441875 0
Post #
442097
of 442157
Four days ago: Italian meta-analysis of 15 small trials.

Published February 4, 2022

Quote:
In contrast, DCV (dendritic cell vaccination) led to significantly longer 1-year OS (HR = 1.936, 95% CI: 1.396–2.85, p = 0.001) and longer 2-year OS (HR = 3.670, 95% CI: 2.291–5.879, p = 0.001) versus control groups. Hence, introducing DCV could lead to increased 1 and 2-year survival of patients by 1.9 and 3.6 times, respectively. Conclusion: Antitumor regimens including DCV can effectively improve mid- term survival in patients suffering glioblastoma multiforme (GBM), but its impact emerges only after one year from vaccination. These data indicate the need for more time to achieve an anti-GBM immune response and suggest additional therapeutics, such as checkpoint inhibitors, to empower an earlier DCV action in (certain) patients affected by a very poor prognosis. https://mdpi-res.com/d_attachment/curroncol/curroncol-29-00075/article_deploy/curroncol-29-00075.pdf

Quote:
It should be noted that, as shown in Table 1, many studies integrated into this meta-analysis are of a non-randomized or historical type. This may reduce the statistical significance of the analysis.




InvestorsHub NewsWire
Robotic Assistance Devices Shipping Large Quantity of Units as Fiscal Year End Approaches • AITX • Feb 8, 2022 9:48 AM

Oncology Pharma Gives Update on Technology, Formulation and Data Creation • ONPH • Feb 8, 2022 9:30 AM

Ammo Inc. Board Approves up to $30 Million Dollar Repurchase Authorization • POWW • Feb 8, 2022 9:04 AM

Splash Beverage Group Signs Distribution Agreement with Anheuser-Busch Distributor Heimark Distributing for TapouT in Southern California • SBEV • Feb 8, 2022 9:03 AM

Mineworx Pleased with Court Decision • MWX • Feb 8, 2022 9:02 AM

Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecoxib Conjugate • ENVB • Feb 8, 2022 8:48 AM

Research Study Proves Calmer Canine Veterinary Therapy Device Resolves Separation Anxiety in Dogs • ADMT • Feb 7, 2022 2:51 PM

WPUR VERY BULLISH at $0.01 On Electric Utility And EV Charging News • ILST • Feb 7, 2022 2:18 PM

Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant - Moves Towards FDA/IND-Submission • IPA • Feb 7, 2022 11:24 AM

RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19 • RDHL • Feb 7, 2022 11:18 AM

HNRC UPDATES ON 18 MONTHS OF ACCOMPLISHMENTS • HNRC • Feb 7, 2022 11:04 AM

Start posting your company's news. Only $200 per official company press release!